Among Dimensional Energy's funders are Microsoft and United. Photo via dimensionalenergy.com

Climatech company Dimensional Energy, which operates a Houston office, has scooped up $20 million in series A funding.

Founded in 2014, Ithaca, New York-based Dimensional Energy specializes in producing decarbonization technology, sustainable aviation fuel, and carbon emissions-derived fuels and materials. South Korea’s Envisioning Partners led the round, with participation from investors such as:

  • United Airlines’ Sustainable Flight Fund
  • Microsoft’s Climate Innovation Fund
  • RockCreek Group’s Smart Aviation Futures fund
  • DSC Investment
  • Delek US
  • Empire State Development
  • Climate Tech Circle

The company also says it’s working toward becoming a certified B Corporation. Businesses that achieve this certification seek to balance purpose and profit.

Dimensional Energy says the $20 million funding round positions it for “significant growth,” enabling it to:

  • Build the world’s first advanced power-to-liquid fuel plant and continue developing commercial power-to-liquid fuel plants.
  • Roll out the company’s initial B2B and B2C products, such as a fossil-free surf wax and a cruelty-free fat alternative for vegan food manufacturers.
  • Evolve the company’s proprietary reactor and catalyst technologies, which are being tested at its pilot plant in Tucson, Arizona.

“The world needs immediate and rapid decarbonization across all sectors, and Dimensional Energy shows great promise as a cleaner and lower-carbon aviation solution alongside reductions in industrial emissions,” Brandon Middaugh, senior director of Microsoft’s Climate Innovation Fund, says in a news release.

Dimensional Energy’s technology transforms carbon dioxide emissions into sustainable aviation fuel (SAF), renewable diesel, and synthetic paraffin that can be refined into more than 6,000 everyday products.

“Dimensional Energy particularly stood out to us for their differentiated technology, exceptional team, and significant progress to date towards producing SAF and other industrial products from CO2,” says Justin Heyman, managing director at RockCreek. “This technology can significantly reduce the environmental footprint of the airline industry.”

------

This article originally ran on EnergyCapital.

The Rice Alliance for Technology and Entrepreneurship handed out awards to the founders of the most promising companies that pitched. Photo courtesy of Slyworks Photography/Rice Alliance

Investors name most promising energy tech startups at annual Houston event

ones to watch

Nearly 100 energy tech startups pitched at the 19th annual Rice Alliance Energy Tech Venture Forum this week — and over a third of those companies are based in the Houston area.

At the conclusion of the event — which took place on Thursday, September 15, at Rice University, and included a day full of company pitches, panels, and thought leadership — 10 startups were deemed the most promising among their peers. The group was voted on by investors attending office hours ahead of the event.

The Rice Alliance for Technology and Entrepreneurship facilitated nearly 700 meetings between 70 investor groups and 90 ventures, according to the organization. The group of presenting companies included participants from Rice's Clean Energy Accelerator's first two cohorts.

Here are 10 of the energy tech industry's most promising companies — and the technology they are working on that's set to disrupt the status quo.

Arolytics

Based in Calgary and founded in 2018, Arolytics is a software company that specializes in emissions management, ESG performance, and regulatory compliance. The company's platform is able to save its users up to 40 percent of their associated measurement costs and emissions management.

Atargis Energy

Atargis Energy is based in Pueblo, Colorado, and is a a member of Rice's second cohort of its Clean Energy Accelerator. The company has developed a twin hydrofoil-based wave energy converter that creates electric power from ocean waves. The technology is paired with real-time sensors and machine learning to optimize power conversion.

Compact Membrane Systems

Based in Delaware, Compact Membrane Systems, is pioneering membrane systems for decarbonizing hard-to-abate chemical manufacturing and industrial carbon capturing. The technology has the potential to revolutionize the chemicals industry.

Dimensional Energy

Dimensional Energy, based in Ithaca, New York, is transforming carbon dioxide into sustainable aviation fuels and products at market competitive prices. The technology integrates carbon capture, electrolysis, and Fischer Tropsch synthesis.

Kanin Energy

Headquartered in Houston, Kanin Energy works with heavy Industry to turn their waste heat into a clean baseload power source. The platform also provides tools such as project development, financing, and operations.

Orbital Sidekick

Orbital Sidekick, based in San Francisco, is an intelligence and analytics company that specializes in remote detection of environmental hazards by way of hyperspectral satellites. The technology provides actionable insights for its customers.

Power to Hydrogen

Based in Columbus, Ohio, Power to Hydrogen has developed an AEM-based electrolysis technology that produces high pressure, high efficiency hydrogen at low cost via water and renewable energy.

Quino Energy

Another Clean Energy Accelerator Class 2 member, Quino Energy produces flow battery systems with over eight hours of energy storage. The batteries are cheaper than lithium-ion alternatives, as well as being safer and easier to scale.

STARS Technology

Based in Richland, Washington, STARS Technology Corp. is commercializing advanced micro-channel chemical process technology that originally was designed for NASA and the Department of Energy. The company's reactors and heat exchangers are compact, energy-efficient, and more.

Syzygy Plasmonics

Houston-based Syzygy Plasmonics is commercializing its light-reacting energy, which would greatly reduce carbon emissions in the chemical industry. The technology originated out of Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”